Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects

Single-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-6016a After Subcutaneous Injection in Healthy Japanese Subjects

This study will assess the safety, tolerability, and pharmacokinetics of DS-6016a after subcutaneous injection in healthy Japanese participants.

Inclusion Criteria:

• Japanese healthy male subjects.
• Age ≥20 and ≤45 years upon providing informed consent.
• Body mass index (BMI) ≥18.5 and <25.0 kg/m^2 at screening.

Exclusion Criteria:

• Have a history of hypersensitivity to any drugs or substances, or being idiosyncratic (eg, having penicillin allergy)
• Have alcohol or drug dependence, etc.